{
    "clinical_study": {
        "@rank": "65643", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate clinical safety issues pertaining to risperidone,\n      to cocaine and to its interaction, and to determine how pretreatment with risperidone\n      modifies the subjective as well as physiological effects of cocaine."
        }, 
        "brief_title": "Infusion Laboratory: Protocol 3 (Risperidone) - 4", 
        "condition": "Cocaine-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Cocaine-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the\n        study and sign informed consent.\n\n        Exclusion Criteria:\n\n        Psychiatric disorder that requires medication therapy. History of seizures. Pregnant\n        and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics.\n        Acute hepatitis. Other medical condtions that deem participation to be unsafe."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": "13", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000339", 
            "org_study_id": "NIDA-3-0010-4", 
            "secondary_id": "Y01-3-0010-4"
        }, 
        "intervention": {
            "intervention_name": "Risperidone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Risperidone"
        }, 
        "lastchanged_date": "August 16, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90025"
                }, 
                "name": "Friends Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Infusion Laboratory: Protocol 3 (Risperidone)", 
        "overall_official": {
            "affiliation": "Friends Research Institute, Inc.", 
            "last_name": "Walter Ling, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "primary_outcome": [
            {
                "measure": "Evidence of change in neurotoxicity based on chore"
            }, 
            {
                "measure": "Degree of drug craving"
            }, 
            {
                "measure": "History, incidence and amount of drug use"
            }, 
            {
                "measure": "Type and severity of stimulant withdrawal symptoms"
            }, 
            {
                "measure": "Characterization of study population"
            }, 
            {
                "measure": "Population incidence of symptoms of depression, po"
            }, 
            {
                "measure": "Frequency and intensity of drug use and sexual beh"
            }, 
            {
                "measure": "Evidence of change in subjective responses to coca"
            }, 
            {
                "measure": "Clinical physiological response to cocaine challen"
            }, 
            {
                "measure": "Degree to which study medication influences change"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000339"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "June 1996", 
        "study_design": "Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1996"
    }, 
    "geocoordinates": {
        "Friends Research Institute": "34.052 -118.244"
    }
}